↓ Skip to main content

Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination

Overview of attention for article published in Tropical Diseases, Travel Medicine and Vaccines, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#11 of 137)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

news
2 news outlets
policy
1 policy source
twitter
7 X users

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination
Published in
Tropical Diseases, Travel Medicine and Vaccines, February 2017
DOI 10.1186/s40794-017-0046-0
Pubmed ID
Authors

John W. Sanders, Todd A. Ponzio

Abstract

The successful development of effective vaccines has been elusive for many of the world's most important infectious diseases. Additionally, much of the population, such as the aged or immunocompromised, are unable to mount an effective immunologic response for existing vaccines. Vectored Immunoprophylaxis (VIP) is a novel approach designed to address these challenges. Rather than utilizing an antigen to trigger a response from the host's immune system as is normally done with traditional vaccines, VIP genetically engineers the production of tailored antibodies from non-hematopoietic cells, bypassing the humoral immune system. Direct administration of genes encoding for neutralizing antibodies has proven to be effective in both preventing and treating several infectious diseases in animal models. While, a significant amount of work has focused on HIV, including an ongoing clinical trial, the approach has also been shown to be effective for malaria, dengue, hepatitis C, influenza, and more. In addition to presenting itself as a potentially efficient approach to solving long-standing vaccine challenges, the approach may be the best, if not only, method to vaccinate immunocompromised individuals. Many issues still need to be addressed, including which tissue(s) makes the most suitable platform, which vector(s) are most efficient at transducing the platform tissue used to secrete the antibodies, and what are the long-term effects of such a treatment. Here we provide a brief overview of this approach, and its potential application in treating some of the world's most intractable infectious diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 81 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 20%
Student > Master 12 15%
Student > Bachelor 11 14%
Student > Ph. D. Student 7 9%
Other 6 7%
Other 10 12%
Unknown 19 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 21%
Medicine and Dentistry 10 12%
Immunology and Microbiology 9 11%
Agricultural and Biological Sciences 5 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 13 16%
Unknown 23 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2021.
All research outputs
#1,236,431
of 23,305,591 outputs
Outputs from Tropical Diseases, Travel Medicine and Vaccines
#11
of 137 outputs
Outputs of similar age
#29,000
of 424,347 outputs
Outputs of similar age from Tropical Diseases, Travel Medicine and Vaccines
#2
of 5 outputs
Altmetric has tracked 23,305,591 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 137 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,347 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.